Arbutus Biopharma Corp (NASDAQ: ABUS) on Tuesday, soared 3.29% from the previous trading day, before settling in for the closing price of $3.34. Within the past 52 weeks, ABUS’s price has moved between $2.30 and $4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 68.89% over the past five years. The company achieved an average annual earnings per share of 11.82%. With a float of $147.08 million, this company’s outstanding shares have now reached $189.44 million.
Let’s look at the performance matrix of the company that is accounted for 73 employees. In terms of profitability, gross margin is 84.13%, operating margin of -1223.89%, and the pretax margin is -1137.64%.
Arbutus Biopharma Corp (ABUS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arbutus Biopharma Corp is 22.38%, while institutional ownership is 54.97%. The most recent insider transaction that took place on Feb 04 ’25, was worth 72,827. In this transaction Chief Financial Officer of this company sold 22,183 shares at a rate of $3.28, taking the stock ownership to the 159,724 shares. Before that another transaction happened on Feb 04 ’25, when Company’s Chief Medical Officer sold 19,348 for $3.28, making the entire transaction worth $63,519. This insider now owns 106,194 shares in total.
Arbutus Biopharma Corp (ABUS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.33% during the next five years compared to 18.41% growth over the previous five years of trading.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Arbutus Biopharma Corp (ABUS) is currently performing well based on its current performance indicators. A quick ratio of 7.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 97.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (NASDAQ: ABUS) saw its 5-day average volume 1.24 million, a positive change from its year-to-date volume of 0.77 million. As of the previous 9 days, the stock’s Stochastic %D was 49.94%. Additionally, its Average True Range was 0.14.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 27.44%, which indicates a significant decrease from 46.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.09% in the past 14 days, which was higher than the 39.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.33, while its 200-day Moving Average is $3.57. Nevertheless, the first resistance level for the watch stands at $3.63 in the near term. At $3.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.93. If the price goes on to break the first support level at $3.33, it is likely to go to the next support level at $3.22. The third support level lies at $3.03 if the price breaches the second support level.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
Market capitalization of the company is 653.75 million based on 189,492K outstanding shares. Right now, sales total 18,140 K and income totals -72,850 K. The company made 1,340 K in profit during its latest quarter, and -19,720 K in sales during its previous quarter.
